Hospitalisation for heart failure and death in new users of SGLT-2 inhibitors in patients with and without cardiovascular disease: the CVDREAL study

M. A. Cavender; A. Norhammar; K. I. Birkeland; M. E. Jorgensen; P. Wilding; K. Khunti; A. Z. Fu; J. Bodegard; B. Blak; E. T. Wittbrodt; M. Thuresson; P. Fenici; N. Hammar; M. Kosiborod; CVD-REAL Investigators StudyGrp

Hospitalisation for heart failure and death in new users of SGLT-2 inhibitors in patients with and without cardiovascular disease: the CVDREAL study

M. A. Cavender, A. Norhammar, K. I. Birkeland, M. E. Jorgensen, P. Wilding, K. Khunti, A. Z. Fu, J. Bodegard, B. Blak, E. T. Wittbrodt, M. Thuresson, P. Fenici, N. Hammar, M. Kosiborod, CVD-REAL Investigators StudyGrp

Original language	Undefined/Unknown
Journal	Diabetologia
Volume	60
Issue number	1
Pages (from-to)	S41
ISSN	0012-186X
Publication status	Published - 1 Sept 2017
Event	53rd Annual Meeting of the European Association for the study of Diabetes EASD - International Fair of Lisbon and MEO Arena, Rua do Bojador, Parque das Nações, Lisabon, Portugal Duration: 11 Sept 2017 → 15 Sept 2017 https://www.easd.org/annual-meeting/easd-2017.html

Conference

Conference	53rd Annual Meeting of the European Association for the study of Diabetes EASD
Location	International Fair of Lisbon and MEO Arena, Rua do Bojador, Parque das Nações
Country/Territory	Portugal
City	Lisabon
Period	11/09/2017 → 15/09/2017
Internet address	https://www.easd.org/annual-meeting/easd-2017.html

Access to Document

https://www.easd.org/virtualmeeting/home.html#!resources/hospitalisation-for-heart-failure-and-death-in-new-users-of-sglt-2-inhibitors-in-patients-with-and-without-cardiovascular-disease-the-cvd-real-study

Cite this

Cavender, M. A., Norhammar, A., Birkeland, K. I., Jorgensen, M. E., Wilding, P., Khunti, K., Fu, A. Z., Bodegard, J., Blak, B., Wittbrodt, E. T., Thuresson, M., Fenici, P., Hammar, N., Kosiborod, M., & StudyGrp, CVD.-REAL. I. (2017). Hospitalisation for heart failure and death in new users of SGLT-2 inhibitors in patients with and without cardiovascular disease: the CVDREAL study. Diabetologia, 60(1), S41. https://www.easd.org/virtualmeeting/home.html#!resources/hospitalisation-for-heart-failure-and-death-in-new-users-of-sglt-2-inhibitors-in-patients-with-and-without-cardiovascular-disease-the-cvd-real-study

Cavender, MA, Norhammar, A, Birkeland, KI, Jorgensen, ME, Wilding, P, Khunti, K, Fu, AZ, Bodegard, J, Blak, B, Wittbrodt, ET, Thuresson, M, Fenici, P, Hammar, N, Kosiborod, M & StudyGrp, CVD-REALI 2017, 'Hospitalisation for heart failure and death in new users of SGLT-2 inhibitors in patients with and without cardiovascular disease: the CVDREAL study', Diabetologia, vol. 60, no. 1, pp. S41. <https://www.easd.org/virtualmeeting/home.html#!resources/hospitalisation-for-heart-failure-and-death-in-new-users-of-sglt-2-inhibitors-in-patients-with-and-without-cardiovascular-disease-the-cvd-real-study>

@article{7be95e726bdd41f286d3721dcb195d1d,

title = "Hospitalisation for heart failure and death in new users of SGLT-2 inhibitors in patients with and without cardiovascular disease: the CVDREAL study",

author = "Cavender, \{M. A.\} and A. Norhammar and Birkeland, \{K. I.\} and Jorgensen, \{M. E.\} and P. Wilding and K. Khunti and Fu, \{A. Z.\} and J. Bodegard and B. Blak and Wittbrodt, \{E. T.\} and M. Thuresson and P. Fenici and N. Hammar and M. Kosiborod and StudyGrp, \{CVD-REAL Investigators\}",

note = "53rd Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), Lisbon, PORTUGAL, SEP 11-15, 2017; 53rd Annual Meeting of the European Association for the study of Diabetes EASD ; Conference date: 11-09-2017 Through 15-09-2017",

year = "2017",

month = sep,

day = "1",

language = "Udefineret/Ukendt",

volume = "60",

pages = "S41",

journal = "Diabetologia",

issn = "0012-186X",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "1",

url = "https://www.easd.org/annual-meeting/easd-2017.html",

}

TY - JOUR

T1 - Hospitalisation for heart failure and death in new users of SGLT-2 inhibitors in patients with and without cardiovascular disease: the CVDREAL study

AU - Cavender, M. A.

AU - Norhammar, A.

AU - Birkeland, K. I.

AU - Jorgensen, M. E.

AU - Wilding, P.

AU - Khunti, K.

AU - Fu, A. Z.

AU - Bodegard, J.

AU - Blak, B.

AU - Wittbrodt, E. T.

AU - Thuresson, M.

AU - Fenici, P.

AU - Hammar, N.

AU - Kosiborod, M.

AU - StudyGrp, CVD-REAL Investigators

N1 - 53rd Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), Lisbon, PORTUGAL, SEP 11-15, 2017

PY - 2017/9/1

Y1 - 2017/9/1

M3 - Tidsskriftartikel

SN - 0012-186X

VL - 60

SP - S41

JO - Diabetologia

JF - Diabetologia

IS - 1

T2 - 53rd Annual Meeting of the European Association for the study of Diabetes EASD

Y2 - 11 September 2017 through 15 September 2017

ER -